ClinicalTrials.gg
RecruitingNCT07002164TIMING-AHFUpdated Mar 19, 2026

Timing of Coronary Angiography in NSTEMI Complicated by Acute HF

An interventional study of Immediate coronary angiography and Delayed coronary angiography in Myocardial Infarction (MI) and Heart Failure, sponsored by Chonnam National University Hospital. Recruiting at 20 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.

Planned enrollment
7th of 11
780 · median 860
Started
2025
the only one that year
No phase
9 of 12
6 open now
Registered
9th of 12
by date

Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 9th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myocardial Infarction by Chonnam National University Hospital, or all of them as a file.
02

Study summary

Study objectives:

To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.

Study hypothesis:

Immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.

Background:

Although current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \<2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.

Study procedure:

Following the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.

Read the detailed description

Acute decompensated heart failure (AHF) is frequently encountered in patients with non-ST-segment elevation myocardial infarction (NSTEMI), and it is known to be associated with worse clinical outcomes that those without heart failure (HF). Although current guidelines recommend immediate invasive strategy for patients with NSTEMI complicated by AHF, its evidence is lack. It is difficult to decide whether to perform early coronary angiography (CAG) according to the guidelines in these high-risk patients due to the risk of procedural complications. Furthermore, the most of randomized trials regarding the timing of CAG in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have excluded these patients, therefore, there is lack of evidence for performing immediate CAG in such cases. In clinical practice, many patients with NSTEMI complicated by AHF did not receive early CAG. There are only two observational studies which investigated this issue. In the Korean nationwide registry data, a total of 1,027 patients with NSTEMI complicated by AHF were analyzed, and 14.5% among study population underwent early CAG within 2 hours according to the guidelines. All-cause mortality at 12 months was not significantly different irrespective of CAG timing. In other single-center study, early CAG \<24 hours was associated with a lower risk of adverse cardiac outcomes compared with delayed CAG ≥24 hours after admission.

Several studies have demonstrated improved clinical outcomes in high-risk patients with NSTE-ACS undergoing early CAG, whereas others have found no significant differences in clinical outcomes. Randomized clinical trials, such as SISCA, ISAR-COOL, RIDDLE-NSTEMI and EARLY, have demonstrated the advantages of early CAG compared to delayed invasive approach (i.e. CAG after stabilization) in high-risk patients with NSTE-ACS. The other trials regarding this issue have failed to show the superiority of early CAG over delayed invasive approach. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF.

Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \<2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.

03

Conditions studied

  • Myocardial Infarction (MI)
  • Heart Failure

Keywords

  • Non-ST-segment elevation myocardial infarction
  • Acute decompensated heart failure
  • Coronary angiography
  • Timing
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥19 years
  • Non-ST-segment elevation myocardial infarction
  • New-onset or worsening of dyspnea ( class ≥2)
  • Pulmonary congestion
  • Patient's or guardian's consent after understanding the study

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock at initial presentation
  • ST-segment elevation myocardial infarction

    • ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or
    • New onset left bundle branch block
    • Posterior wall myocardial infarction
  • angina
  • Life threatening ventricular arrhythmias
  • \<1 year
  • Apparently non-ischemic cause of HF
  • Pregnancy and lactation
  • History of coronary artery bypass grafting (CABG), or planned CABG
  • Patient's refusal to participate in study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
780 participants (estimated)

Study arms

  • Experimental
    Immediate coronary angiography within 2 hours after diagnosis of non-ST-segment elevation myocardial

    Coronary angiography will be performed within 2 hours after diagnosis of non-ST-segment elevation myocardial infarction.

    Procedure: Immediate coronary angiography

  • Active comparator
    Delayed coronary angiography after stabilization of acute decompensated heart failure

    Coronary angiography will be performed after disappearance of symptoms and signs of acute decompensated heart failure.

    Procedure: Delayed coronary angiography

Interventions

  • ProcedureImmediate coronary angiography

    Immediate coronary angiography ≤2 hours after randomization

  • ProcedureDelayed coronary angiography

    Delayed coronary angiography after stabilization

06

What researchers measure

Primary outcomes

  1. A cumulative incidence rate of all-cause death, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF)

    Time frame: 1 year

Secondary outcomes

  1. A cumulative incidence rate of all-cause death, non-fatal MI, or hospitalization for HF

    Time frame: 1, 6, 24, 36 months

  2. All-cause death

    Time frame: 1, 6, 12, 24, 36 months

  3. Non-fatal MI

    Time frame: 1, 6, 12, 24, 36 months

  4. Hospitalization for HF

    Time frame: 1, 6, 12, 24, 36 months

  5. Cardiovascular death

    Time frame: 1, 6, 12, 24, 36 months

  6. Recurrent ischemia

    Recurrent ischemia is defined as repeated episodes of ischemic symptoms needing emergent coronary angiography with any of the following signs: * Electrocardiographic changes indicating myocardial ischemia * Ventricular arrhythmias * New-onset pulmonary edema * Cardiogenic shock

    Time frame: 1, 6, 12, 24, 36 months

  7. All unplanned revascularization

    Time frame: 1, 6, 12, 24, 36 months

  8. Definite or probable stent thrombosis

    Time frame: 1, 6, 12, 24, 36 months

  9. Stroke

    Time frame: 1, 6, 12, 24, 36 months

  10. Major bleeding by Bleeding Academic Research Consortium

    Time frame: 1, 6, 12, 24, 36 months

  11. Acute kidney injury (AKI) and AKI requiring renal replacement therapy

    Time frame: Up to 7 days

  12. In-hospital death rate from any cause

    Time frame: Up to 30 days

  13. In-hospital death rate from cardiovascular cause

    Time frame: Up to 30 days

07

Study locations

13 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2030, 57 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 57 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2025
First posted
Jun 3, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Apr 30, 2030
CompletionEst.
Apr 30, 2032
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07002164
Lead sponsor
Chonnam National University Hospital
Responsible party
Min Chul Kim (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Jun 3, 2025
Start date
Jul 15, 2025
Primary completion
Apr 30, 2030 (estimated)
Completion
Apr 30, 2032 (estimated)
Last update
Mar 19, 2026

Study contacts

Youngkeun Ahn, Professor
Contact
cecilyk@hanmail.net
82-62-220-4764 ext. 82-62-220-4764
Min Chul Kim, Professor
Contact
kmc3242@hanmail.net
82-62-220-6578 ext. 82-62-220-6578

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion